This is helpful! Thanks for the links. You have my word that I will be reaching out to Justin Kirkland this week and inquiring about his work with BOL. I have some ideas for tweaking the molecule but they may not be commercially viable- that is always the "catch," when it comes to denovo therapeutic development. Cool ideas are often unprofitable!
I apologize for not checking in more often. Lately my days have involved research on a rare neurodegenerative disorder called Pantothenate Kinase-associated Neurodegeneration. My teammates and I are working on resurrecting an abandoned program that we believe can be improved and used to give hope to the patients and families who grapple with this debilitating disease. I've also been researching motility agents for gastroparesis in Parkinson's. Neuro/CNS does not have the attention, as a therapeutic area, that I believe it needs.
I have been discussing CH along with other disease states with my colleagues. We continue to search and have discussed BOL, as one of my colleagues had looked it over in the 2014-16' years. I am not sure if I mentioned it on here, but I had a conference call with Compass Pathways and encouraged them to develop their crystalline polymorph of psilocybin for CH.
To the extent that I can help any of you with anything (aside from continuing the quest to bring new therapeutics to market for CH) please reach out. I left my personal info in a previous post, and will always welcome a message from a Cluster Head or advocate.
Hope & Strength,
-JJF